Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures
Status:
Withdrawn
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, randomized, double blinded, placebo controlled trial that aims to
investigate the hypothesis that early administration of tranexamic acid (TXA) following
diagnosis of hip fracture will lower pre and postoperative blood loss and transfusion rates.
Patients who present to the hospital with a hip fracture will be recruited and randomized
into two treatment arms. The treatment group will receive 1950mg of oral TXA (three tablets,
650 mg each) and the control group will be given three tablets of oral placebo while in the
Emergency Department. Patients will then be admitted to the Orthopaedic Trauma service and
treated surgically with cephalomedullary nail, hemiarthroplasty, sliding hip screw,
percutaneous screws, or total hip arthroplasty.